Cargando…
Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722373/ https://www.ncbi.nlm.nih.gov/pubmed/29220392 http://dx.doi.org/10.1371/journal.pone.0189146 |
_version_ | 1783284998434979840 |
---|---|
author | Tshimanga, Mufuta Makunike-Chikwinya, Batsirai Mangwiro, Tonderayi Tapiwa Gundidza, Patricia Chatikobo, Pesanai Murenje, Vernon Herman-Roloff, Amy Kilmarx, Peter H. Holec, Marrianne Gwinji, Gerald Mugurungi, Owen Murwira, Munyaradzi Xaba, Sinokuthemba Barnhart, Scott Feldacker, Caryl |
author_facet | Tshimanga, Mufuta Makunike-Chikwinya, Batsirai Mangwiro, Tonderayi Tapiwa Gundidza, Patricia Chatikobo, Pesanai Murenje, Vernon Herman-Roloff, Amy Kilmarx, Peter H. Holec, Marrianne Gwinji, Gerald Mugurungi, Owen Murwira, Munyaradzi Xaba, Sinokuthemba Barnhart, Scott Feldacker, Caryl |
author_sort | Tshimanga, Mufuta |
collection | PubMed |
description | Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce MC uptake. Reducing promotion of HIV testing within MC settings and promoting device-based MC may speed MC scale-up. To assess safety and efficacy of PrePex MC device among HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive men in Zimbabwe. METHODS: We aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision. RESULTS: Among 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35–49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs (p = 0.0003). All AEs were device displacements resulting in surgical MC and, subsequently, complete healing. CONCLUSION: Male circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections. |
format | Online Article Text |
id | pubmed-5722373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57223732017-12-15 Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe Tshimanga, Mufuta Makunike-Chikwinya, Batsirai Mangwiro, Tonderayi Tapiwa Gundidza, Patricia Chatikobo, Pesanai Murenje, Vernon Herman-Roloff, Amy Kilmarx, Peter H. Holec, Marrianne Gwinji, Gerald Mugurungi, Owen Murwira, Munyaradzi Xaba, Sinokuthemba Barnhart, Scott Feldacker, Caryl PLoS One Research Article Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce MC uptake. Reducing promotion of HIV testing within MC settings and promoting device-based MC may speed MC scale-up. To assess safety and efficacy of PrePex MC device among HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive men in Zimbabwe. METHODS: We aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision. RESULTS: Among 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35–49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs (p = 0.0003). All AEs were device displacements resulting in surgical MC and, subsequently, complete healing. CONCLUSION: Male circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections. Public Library of Science 2017-12-08 /pmc/articles/PMC5722373/ /pubmed/29220392 http://dx.doi.org/10.1371/journal.pone.0189146 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Tshimanga, Mufuta Makunike-Chikwinya, Batsirai Mangwiro, Tonderayi Tapiwa Gundidza, Patricia Chatikobo, Pesanai Murenje, Vernon Herman-Roloff, Amy Kilmarx, Peter H. Holec, Marrianne Gwinji, Gerald Mugurungi, Owen Murwira, Munyaradzi Xaba, Sinokuthemba Barnhart, Scott Feldacker, Caryl Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title | Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title_full | Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title_fullStr | Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title_full_unstemmed | Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title_short | Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe |
title_sort | safety and efficacy of the prepex device in hiv-positive men: a single-arm study in zimbabwe |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722373/ https://www.ncbi.nlm.nih.gov/pubmed/29220392 http://dx.doi.org/10.1371/journal.pone.0189146 |
work_keys_str_mv | AT tshimangamufuta safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT makunikechikwinyabatsirai safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT mangwirotonderayi safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT tapiwagundidzapatricia safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT chatikobopesanai safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT murenjevernon safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT hermanroloffamy safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT kilmarxpeterh safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT holecmarrianne safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT gwinjigerald safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT mugurungiowen safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT murwiramunyaradzi safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT xabasinokuthemba safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT barnhartscott safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe AT feldackercaryl safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe |